Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Finger Prick Test Could Predict COVID-19 Complications from Drop of Blood

By LabMedica International staff writers
Posted on 12 Sep 2022

Many people died from COVID-19 because of the rapid development of complications caused by the so-called immune system-induced cytokine storm during which the body releases too many inflammatory proteins called cytokines into the blood too quickly. More...

Symptoms include high fever, severe fatigue and sometimes organ failure. A cytokine storm can lead to abnormal blood clotting through the body’s blood vessels. For COVID-19 patients, it can lead to complications that contribute to respiratory difficulties and ultimately cause the patient’s death. But could some of those who died from COVID-19 and other infectious diseases have been saved by a diagnosis that predicts how severe their cases will be and provides timelier treatment?

An interdisciplinary team of engineers and doctors at Tulane University (New Orleans, LA, USA) hopes to answer that question with the development of new technology designed to detect severe COVID complications such as thrombosis, a condition in which blood clots block veins and arteries. The team has received a nearly USD 600,000 Trailblazer Award from the National Institute of Biomedical Imaging and Bioengineering to take on research that will lead to tests that can predict the severity of infectious diseases. The goal is to develop a diagnostic test that uses a drop of blood from a finger prick – a test that could be performed at a hospital, in a clinic or at home.

“Many patients who died from COVID-19 and other infectious diseases developed severe thrombotic complications shortly after disease symptoms were manifested,” said Damir Khismatullin, PhD, an associate professor of biomedical engineering in the Tulane School of Science and Engineering. “Their lives could be saved by predictive diagnosis of disease severity and timely treatment. However, tests that effectively predict the severity of infectious diseases are not available yet.”

Related Links:
Tulane University


Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The new diagnostic platform aims to detect lymphatic disease earlier and more precisely (Photo courtesy of 123RF)

Diagnostic Toolbox to Rapidly and Reliably Detect Lymphatic Disease

The lymphatic system plays a crucial role in fluid balance and immune defense, but remains one of the hardest systems in the body to diagnose when it malfunctions. Because lymphatic vessels are tiny, translucent,... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.